Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease. (29th May 2022)

• Record Type: Journal Article
• Authors: Tsipotis, Evangelos; Frey, Sarah; Connolly, Caoilfhionn; Werbel, William A.; Chowdhury, Reezwana; Dudley-Brown, Sharon; Melia, Joanna M.; Parian, Alyssa M.; Truta, Brindusa; Yu, Huimin; Selaru, Florin M.; Segev, Dorry L.; Lazarev, Mark
• Is Part Of: American journal of gastroenterology. Volume 117:Number 5(2022)
• Page Start: 798
• Page End: 801
• Publication Date: 2022-05-29
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.14309/ajg.0000000000001668
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : INTRODUCTION: The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations. METHODS: We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series. RESULTS: Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy. DISCUSSION: Larger longitudinal studies are required to define the response in IBD population and its clinical impact.